Systemic lupus erythematosus;Lúpus eritematoso sistêmico

Revista Brasileira de Medicina

Volumn 66, Issue 9, 2009, Pages 274-285

  De Assis, Marcos Renate ^a   Baaklini, César Emile ^a  

^a FACULDADE DE MEDICINA DE MARÍLIA   (Brazil)

Author keywords

Diagnosis; Review; Systemic lupus erythematosus; Treatment

Indexed keywords

ANTICOAGULANT AGENT; ANTIINFLAMMATORY AGENT; ANTIMALARIAL AGENT; AUTOANTIBODY; AZATHIOPRINE; B CELL ACTIVATING FACTOR; BELIMUMAB; CD40 LIGAND MONOCLONAL ANTIBODY; CLOFAZIMINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DANAZOL; DAPSONE; DNA ANTIBODY; EPRATUZUMAB; ETRETINATE; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; INFLIXIMAB; INTERLEUKIN 1 ANTIBODY; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; OCRELIZUMAB; RETINOID; RITUXIMAB; STEROID; THALIDOMIDE; UNINDEXED DRUG;

ARTICLE; AUTOIMMUNITY; CARDIOVASCULAR DISEASE; DIFFERENTIAL DIAGNOSIS; EMOTIONAL STRESS; GENETIC PREDISPOSITION; HUMAN; INFECTIOUS COMPLICATION; INFLAMMATION; PHYSICAL STRESS; PROGNOSIS; SUN EXPOSURE; SURVIVAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 71249091219     PISSN: 00347264     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature. The American College of Rheumatology Nomenclatureand Case Definitions for Neuropsychiatric Lupus Syndrome. Arthritis Rheum, 42:599-608, 1999.
2. Appenzeller, Simone; Costallat, Lilian Tereza Lavras. Comprometimento primário do sistema nervoso central no lúpus eritematoso sistêmico / Primary central nervous system involvement in systemic lupus eritematosus. Rev Bras Reumatol, 2003; 43(1):20-25.
3. Balow JE, Austin HA. Therapy of membranous nephropathy in systemic Lupus erythematosus. Semin Nephrol, 2003; 23:386-391 (Pubitemid 37022042)
4. Bansal VK, Beto JA. Treatment of Lupus nephritis: a meta-analysis of clinical trial. Am J Kidney Dis, 29:193-199, 1997.
5. Barile L, Lavalle C. Transverse myelitis in systemic Lupus erythematosus: the effect of intravenous pulse methylprednisolone and cyclophosphamide. J Rheumatol, 1992; 19:370-372
6. Bezerra ELM, Vilar MJP, Barbosa OFC et al. Lúpus Eritematoso Sistêmico (LES): Perfil Clínico-Laboratorial dos Pacientes do Hospital Universitário Onofre Lopes (UFRN-Natal/Brasil) e Índice de Dano nos Pacientes com Diagnóstico Recente. Rev Bras Reumatol, 2005; 45(6):339-342.
7. Burt RK, Traynor A, Statkute L et al. Non-myeloablative hematopoietic stem cell transplantation for systemic Lupus erythematosus. JAMA, 2006; 295:527-535. (Pubitemid 43200347)
8. Carneiro JR, Sato EI. Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic Lupus erythematosus. J Rheumatol, 1999; 26:1275-1279 (Pubitemid 29268077)
9. Cervera H, Jara LJ, Pizarro S. Danazol for systemic Lupus erythematosus with refractory autoimmune thrombocytopenia or Evans syndrome. J Rheumatol, 1995; 22:1867-1871
10. Cervera R, Khamashta MA, Font J et al. European work ingparty on Systemic Lupus erythematosus. Systemic Lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1000 patients. Medicine, 1993; 72:113-124
11. Chahade WH, Sato EI, Costallat LTL, Andrade LEC. Occasional series: Lupus Around the World. Systemic Lupus in São Paulo/Brazil: a clinical and laboratory overview. Lupus, 4:100-103, 1995.
12. Chan TM, Li FK, Tang CSO et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative Lupus nephritis. N Engl J Med, 2000; 343:1156-1162 (Pubitemid 30781986)
13. Committee on Systemic Lupus Erythematosus Response Criteria for Fatigue. Measurement of fatigue in systemic lupus erythematosus: a systematic review. Arthritis Rheum. 2008; 59(7):1049.
14. Contreras G, Pardo V, Ledercq B, Lenz O, Tozman E, Onan Pet al. Sequential therapies for proliferative Lupus Nephritis. N Engl J Med, pp. 971-80, 2001.
15. Cordeiro AC, Isenberg DA. Novel Therapies In Lupus - Focus On Nephritis. Acta Reumatol Port. 2008;33:157-169.
16. de Carvalho JF, Hanaoka B, Szyper-Kravitz M, Shoenfeld Y. C-Reactive protein and its implications in systemic lupus erythematosus. Acta Reumatol Port, 2007 Oct-Dec; 32(4):317-322
17. Dooley MA. Clinical and laboratory features of Lupus nephritis. In: Dubois' Lupus erythematosus. Wallace DJ, Hahn BH (eds).Philadelphia: Lippincott, Williams & Wilkins, pp. 1112-1130, 2007.
18. Fernando MM, Stevens CR, Walsh EC, et al. Defining the role of the MHC in autoimmunity: a review and pooled analysis. PLoS Genet, 2008 Apr 25;4(4):e1000024.
19. Flanc RS, Roberts MA, Strippoli GF et al. Treatment of diffuse proliferative Lupus nephritis: a meta-analysis of randomized controlled trials. Am. J Kidney Dis, 2004; 43:197-208.
20. Gilles, Joann. Pulmonary and thrombotic manifestations of systemic lupus erythematosus. Chest 2008 Jan;133(1):271-80. Errata in Chest 2008 Mar;133(3):832.
21. Gladman DD, Urowitz, MB. Prognosis, mortality and morbidity in systemic Lupus erythematosus. In: Dubois' Lupus erythematosus. Edit Wallace DJ, Hahn BH. Lippincott, Williams A; Wilkins, Philadelphia, pp. 1255-1273, 2001.
22. Gunnarsson I, Sundelin B, Jonsdottir T et al. Histopathologic and Clinical outcome of rituximab treatment in patients with cyclophosphamide- resistant proliferative Lupus nephritis. Arthritis Rheum, 2007; 56:1263-1272 (Pubitemid 46608651)
23. Hahn BH. An overview of the pathogenesis of systemic Lupus erythematosus. In: Dubois' Lupus erythematosus. Wallace DJ, Hahn BH (eds). Philadelphia: Lippincott, Williams & Wilkins, pp. 847-896, 2001.
24. Hall RP, Lawley TJ, Smith HR et al. Bullous eruption of systemic Lupus erythematosus: Dramatic response to dapsone therapy. Ann Inter Med, 1982; 97:165-170
25. Hochberg MC. Updating the American College of Rheumatology revised criteria for the Classification of systemic lupus erythematosus. Letter. Arthritis Rheum, 1997; 40:1725.
26. Houssiau FA, Vasconcelos C, D Cruz D et al. Immunossupressive therapy in Lupus nephritis. The Euro-Lupus Nephritis Trial, a randomized trial of low dose versus high dose intravenous cyclophosphamide. Arthritis Rheum, 46(8):2121-2123, 2002.
27. Hugle T, van Laar JM. Stem cell transplantation for rheumatic autoimmune diseases. Arthritis Res Ther, 2008;10(5):217.
28. III Consenso Brasileiro para pesquisa de autoanticorpos em células HEp-2 (FAN). Revista Brasileira de Reumatologia, 2009; 49(2).
29. Illei GG, Austin HA, Crane M et al. Combination therapy with pulse cyclophosphamide plus pulse methilprednisolone improves long-term renal outcome without adding toxicity inpatients with Lupus nephritis. Ann Intern Med, 134:248-257, 2001. (Pubitemid 32799338)
30. Meinão IM, Sato EI, Andrade LE, Ferraz MB, Atra E. Controlled trial with chloroquine diphosphate in systemic lupus erythematosus. Lupus, 1996; 5:237-241 (Pubitemid 26197484)
31. Melikoglu MA, Melikoglu M. The clinical importance of lymphadenopathy in systemic lupus erythematosus. Acta Reumatol Port, 2008 OctDec;33(4):402-406
32. Pereira IA, Borba EF. The role of inflammation, humoral and cell mediated autoimmunity in the pathogenesis of atherosclerosis. Swiss Med Wkly, 2008 Sep 20;138(37-38):534-539
33. Petri M, Jones RJ, Brodsky RA. High-dose cyclophosphamide without stem cell transplantation in systemic Lupus erythematosus. Arthritis Rheum, 2003; 48:166-173 (Pubitemid 36091660)
34. Pistiner M, Wallace DJ, Nessim S et al. Lupus erythematosus in the 1980s: a survey of 570 patients. Semin Arthritis Rheum, 21:55-64, 1991.
35. Ruggenenti P, Perna A, Benini R et al. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric non-diabetic nephropathy. Lancet, 1997; 349:1857-1863
36. Sada KE, Makino H. Usefulness of ISN/RPS classification of lupus nephritis. J Korean Med Sci, 2009 Jan;24 Suppl:S7-10.
37. Sato EI, Assis LS, Lourenzi VP, Andrade LE. Long-term thalidomide use in refractory cutaneous lesions of systemic lupus erythematosus. Rev Assoc Med Bras, 1998; 44:289-293
38. Systemic Lupus Erythematosus in Current Medical Diagnosis & Treatment - 47th Ed, 2008 - McPhee SJ & Papadakis MA. McGraw Hill Companies.
39. Villar MJ, Sato EL. Estimating the incidence of systemic Lupus erythematosus in a tropical region (Natal, Brazil). Lupus, 11:528-532, 2002.
40. Von Feldt JM. Premature atherosclerotic cardiovascular disease and systemic lupus erythematosus from bedside to bench. Bull NYU Hosp Jt Dis, 2008;66(3):184-187
41. Wallace DJ. Differential diagnosis and disease associations. In: Dubois Lupus erythematosus. Wallace DJ, Hahn BH (eds). Philadelphia: Lippincott, Williams & Wilkins, pp. 959-983, 2001.
42. Weening JJ, D Agati VD, Schwartz MM et al. The classification of glomerulonephritis in systemic Lupus erythematosus revisited. J. Am Soc Nephrology, 2004; 15:241-250 (Pubitemid 38140764)
43. Zonana-Nacach A, Roseman JM, McGwin G, Friedman AW, Baethge BA, Reveille JD, et al, and the LUMINA Study Group. Systemic lupus erythematosus in three ethnic groups. VI. Factors associated with fatigue within 5 years of criteria diagnosis. Lupus, 2000; 9:101-109